Sermorelin (10 mg) is a synthetic peptide composed of the first 29 amino acids of endogenous human growth hormone–releasing hormone (GHRH). This truncated structure represents the biologically active portion of the full-length hormone, making it a valuable tool in endocrine and physiological research.

Sermorelin is structurally identical to the functional GHRH(1–29) fragment, with a molecular formula of C₁₄₉H₂₄₆N₄₄O₄₂S and a molecular weight of 3357.9 g/mol. It is supplied as a ≥95% pure, lyophilized powder in a 10 mg vial, enabling precise dosing and reproducibility in controlled laboratory settings.

Sermorelin is primarily used to assess growth hormone (GH) release and related signaling pathways.

Sermorelin (10 mg) Key Features & Specs

• Subcategory: Muscle Growth & Performance Peptides
• Strength: 10 mg
• CAS: 86168-78-7
• Chemical Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• Molecular Weight: 3357.9 g/mol
• Peptide Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
• Synonym: GHRH (1–29)

For laboratory research use only.

Sermorelin (10 mg) Research Uses

Sermorelin is used in research focused on growth hormone regulation and endocrine signaling. It stimulates GH release from the anterior pituitary, helping researchers examine hormone production and balance within the somatotropic axis.

Beyond GH release, Sermorelin is applied in studies of metabolism, tissue repair, and the interactions between endocrine and neurological signaling. The peptide is also used to investigate downstream effects such as protein synthesis, cellular turnover, and metabolic adaptation.

Sermorelin has been studied in research on sleep cycles, aging-related hormonal changes, and stress-related endocrine responses, helping to elucidate how hormone rhythms are regulated.

In analytical research, Sermorelin serves as a reference compound to identify GHRH analogues, aid in refining detection techniques, and improve assay sensitivity.

Sermorelin (10 mg) Insights & Observed Findings

Sermorelin is a short-acting growth hormone secretagogue with a rapid clearance profile.

• In clinical research settings, intravenous doses of approximately 1 µg/kg have been used to assess pituitary GH responsiveness and hormone reserve capacity under experimental conditions.
• Subcutaneous administration has been explored in pediatric research cohorts, with doses of around 30 µg/kg used to assess growth-related markers and hormone levels. Findings remain specific to study conditions and should not be generalized.
• In preclinical research, Sermorelin is used in animal models to study the GH/IGF axis and its effects on protein metabolism, extracellular matrix activity, and tissue repair. It has also been examined in cardiac and vascular models, focusing on hormone signaling's influence on structural adaptation.
• Sermorelin also plays a key role in laboratory method development, with techniques like liquid chromatography–mass spectrometry used to detect and quantify GHRH analogues, reinforcing its value as a research tool.

Observed findings underscore Sermorelin’s utility in studying endocrine signaling, but outcomes depend on experimental design and conditions.

Sermorelin (10 mg) Handling & Storage

• Store as a lyophilized powder at –20°C in a sealed container.
• Protect from light and moisture to maintain peptide stability.
• Allow the vial to reach room temperature before opening to reduce condensation.
• Reconstitute using a sterile aqueous solvent.
• After reconstitution, store the solution at 2–8°C for short-term use.
• Aliquot to minimize repeated freeze-thaw cycles and ensure consistency.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clin Interv Aging. 2006;1(4):307-308. doi:10.2147/ciia.2006.1.4.307
2. Prakash A, Goa KL. Sermorelin. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007
3. Pont L, Alechaga É, Terrero A, Monfort N, Ventura R. Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. J Chromatogr A. 2020;1631:461548. doi:10.1016/j.chroma.2020.461548